文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗第一年内应答患者的长期结局:935例患者汇总分析

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
PubMed 文献 · Eur J Cancer · 2024-11-16

该汇总分析纳入CheckMate 069、066和067研究中935例初治晚期黑色素瘤患者,评估治疗3、6或12个月内RECIST应答对长期生存的预测价值。12个月界标分析显示,联合组应答者5年OS为82% vs 非应答者40%(HR=0.23),单药组为76% vs 32%(HR=0.22)。

要点

  • 联合组任意时间应答率58%(239/409),单药组44%(230/526)。
  • 12个月界标分析中,联合组应答者5年OS 82% vs 非应答者40%(HR=0.23)。
  • 单药组应答者5年OS 76% vs 非应答者32%(HR=0.22)。

核心结论

  • 治疗最初数月内评估的临床应答是长期生存的强预测因素,即使在高LDH和低PD-L1表达等预后不良生物标志物患者中亦然。

研究设计与样本

  • 汇总CheckMate 069、066和067研究数据,纳入935例初治晚期黑色素瘤患者,接受纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗。
  • 采用3、6或12个月界标分析以减少永恒时间偏倚,评估RECIST应答对长期生存的预测价值。

主要发现

  • 任意时间应答率:联合组58%(239/409),单药组44%(230/526)。
  • 12个月界标分析5年OS:联合组应答者82% vs 非应答者40%(HR=0.23 [95%CI 0.15-0.35]);单药组应答者76% vs 非应答者32%(HR=0.22 [95%CI 0.16-0.31])。
  • 12个月界标分析PFS率:联合组应答者83% vs 非应答者32%;单药组应答者69% vs 非应答者46%。
  • 3个月和6个月界标分析也观察到应答与5年OS和PFS的强关联,超过70%的应答在最初3个月内观察到。
  • 多因素分析显示应答率与基线LDH和PD-L1状态相关,但界标分析中应答与长期生存的关联在高LDH和低PD-L1表达患者中仍维持。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year data of 935 responder and non-responder patients at various time points after treatment initiation in CheckMate 069, 066, and 067 studies. PATIENTS AND METHODS: Treatment-naive advanced melanoma patients received nivolumab+ipilimumab or nivolumab monotherapy. To decrease immortal time bias, 3-, 6-, or 12-month overall survival (OS) and progression-free survival (PFS) landmark analyses were performed. Association between characteristics and response was evaluated by univariate and multivariate analyses. RESULTS: Response rates at any time were 58 % (239/409) for nivolumab+ipilimumab and 44 % (230/526) for nivolumab monotherapy. In 12-month landmark analyses, 5-year OS rates for responders versus non-responders were 82 % versus 40 % with nivolumab+ipilimumab (HR=0.23 [95 % CI, 0.15-0.35]) and 76 % versus 32 % with nivolumab monotherapy (HR=0.22 [95 % CI, 0.16-0.31]). PFS rates were 83 % versus 32 % and 69 % versus 46 %, respectively. Similar strong associations between response at 3 and 6 months and 5-year OS and PFS were also observed with more than 70 % of the responses observed in the first 3 months. Response rates correlated with baseline LDH and PD-L1 status by multivariate analysis but the association between response and long-term survival was maintained in landmark analyses even among patients with high LDH and low PD-L1 expression. CONCLUSION: Clinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic biomarkers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Robert C, Long GV, Larkin J, et al. Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients. Eur J Cancer. 2024. PMID: 39612757. doi:10.1016/j.ejca.2024.115119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。